Trial Search Results
In Vivo Characterization of Macrophages in Pediatric Patients With Malignant Brain Tumors Using Ferumoxytol-enhanced MRI
This pilot early phase I trial studies how well ferumoxytol-enhanced magnetic resonance imaging (MRI) correlates with inflammatory (macrophage) responses in pediatric patients with malignant brain tumors. If there is good correlation, ferumoxytol-enhanced MRI can serve as a noninvasive imaging biomarker of inflammation.
Stanford is currently accepting patients for this trial.
Lead Sponsor:
Michael Iv
Collaborator: National Cancer Institute (NCI)
Stanford Investigator(s):
Intervention(s):
- Diagnostic Test: Diagnostic (ferumoxytol-enhanced MRI)
- Procedure: Surgery
- Drug: Ferumoxytol
- Other: Tissue Analysis
Phase:
Early Phase 1
Eligibility
Inclusion Criteria:
- Any patient with suspected malignant brain tumor on diagnostic MR imaging who will
undergo a resection
Exclusion Criteria:
- Informed consent cannot be obtained either from the patient or legal representative
- Severe coexisting or terminal systemic disease that may interfere with the conduct of
the study
- Contraindication to MRI (metal implants)
- Hemosiderosis/hemochromatosis
- Iron overload from any cause (not just hemosiderosis or hemochromatosis), even if
secondary to frequent blood transfusions, severe chronic hemolysis, excess dietary or
parenteral iron, or any other etiology
- Known hypersensitivity to ferumoxytol or any of its components
- Pregnant patients
Ages Eligible for Study
2 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Paymon Rezaii
650-743-8336
Recruiting